CAS 864821-90-9
:5-[[[(2S)-2-Amino-3-[4-(aminocarbonyl)-2,6-diméthylphényl]-1-oxopropyl][(1S)-1-(5-phényl-1H-imidazol-2-yl)éthyl]amino]méthyl]-2-méthoxybenzoïque acide
- Eluxadoline
- 5-[[[(2S)-2-Amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid
- Benzoic acid, 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxy-
- JNJ 27018966
- Benzoic acid, 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxy-
Eluxadoline
CAS :Produit contrôléFormule :C32H35N5O5Couleur et forme :Off-WhiteMasse moléculaire :569.65Eluxadoline-glucuronide
CAS :Produit contrôléEluxadoline-glucuronide is a custom synthesis that has been modified by fluorination, methylation, and monosaccharide modification. It has a CAS No., which is 637259-71-2. Eluxadoline-glucuronide is an oligosaccharide with glycosylation and sugar composition. The carbohydrate complex is composed of saccharides and polysaccharides. This product can be used in the production of pharmaceuticals, agrochemicals, or other chemical substances.
Degré de pureté :Min. 95%Eluxadoline-13C,d3 Dihydrochloride
CAS :Produit contrôléApplications Eluxadoline-13C,d3 Dihydrochloride is labelled Eluxadoline Dihydrochloride (E508200) which is a mixed μ opioid receptor agonist / δ opioid receptor antagonist used in the treatment and modulation of gastrointestinal function. Used in patients with diarrhea-predominant IBS.
References Wade, P. et al.: Brit. J. Pharm., 167, 1111 (2012); Breslin, H. et al.: Bioorg. Med. Chem. Lett., 22, 4869 (2012)Formule :C31CH34D3Cl2N5O5Couleur et forme :NeatMasse moléculaire :573.662Eluxadoline deuterated
CAS :Produit contrôléEluxadoline is a drug that has been developed to treat the symptoms of irritable bowel syndrome with constipation. This medicine is a selective agonist at opioid receptors, which are found in the bowel and the central nervous system. Eluxadoline has demonstrated efficacy in patients with inflammatory bowel diseases, including ulcerative colitis, Crohn's disease, and pouchitis. The drug is not metabolized by cytochrome P450 enzymes and does not inhibit or induce these enzymes. It also does not bind to serum proteins such as albumin or α1-acid glycoprotein. Side effects can include nausea, dizziness, headache, and diarrhea.
Formule :C32H35N5O5Degré de pureté :Min. 95%Masse moléculaire :569.65 g/mol


